These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9300685

  • 1. Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels.
    Kalechman Y, Gafter U, Da JP, Albeck M, Alarcon-Segovia D, Sredni B.
    J Immunol; 1997 Sep 15; 159(6):2658-67. PubMed ID: 9300685
    [Abstract] [Full Text] [Related]

  • 2. Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention.
    Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, Sredni B.
    J Immunol; 2002 Jul 01; 169(1):384-92. PubMed ID: 12077268
    [Abstract] [Full Text] [Related]

  • 3. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101.
    Sredni B, Tichler T, Shani A, Catane R, Kaufman B, Strassmann G, Albeck M, Kalechman Y.
    J Natl Cancer Inst; 1996 Sep 18; 88(18):1276-84. PubMed ID: 8797767
    [Abstract] [Full Text] [Related]

  • 4. Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101.
    Kalechman Y, Sredni B.
    J Immunol; 1996 Jul 15; 157(2):589-97. PubMed ID: 8752906
    [Abstract] [Full Text] [Related]

  • 5. The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody.
    Blank M, Sredni B, Albeck M, Mozes E, Shoenfeld Y.
    Clin Exp Immunol; 1990 Mar 15; 79(3):443-7. PubMed ID: 2317948
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3.
    Kalechman Y, Gafter U, Weinstein T, Chagnac A, Freidkin I, Tobar A, Albeck M, Sredni B.
    J Biol Chem; 2004 Jun 04; 279(23):24724-32. PubMed ID: 15001575
    [Abstract] [Full Text] [Related]

  • 7. Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop.
    Sredni B, Weil M, Khomenok G, Lebenthal I, Teitz S, Mardor Y, Ram Z, Orenstein A, Kershenovich A, Michowiz S, Cohen YI, Rappaport ZH, Freidkin I, Albeck M, Longo DL, Kalechman Y.
    Cancer Res; 2004 Mar 01; 64(5):1843-52. PubMed ID: 14996748
    [Abstract] [Full Text] [Related]

  • 8. Induction of acute phase proteins in mice and humans by treatment with AS101, an immunomodulator with radioprotective properties.
    Kalechman Y, Shani A, Albeck M, Sredni B.
    Immunopharmacology; 1995 Mar 01; 29(2):149-58. PubMed ID: 7539780
    [Abstract] [Full Text] [Related]

  • 9. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate.
    Kalechman Y, Zuloff A, Albeck M, Strassmann G, Sredni B.
    Blood; 1995 Mar 15; 85(6):1555-61. PubMed ID: 7888674
    [Abstract] [Full Text] [Related]

  • 10. Novel involvement of the immunomodulator AS101 in IL-10 signaling, via the tyrosine kinase Fer.
    Hayun R, Shpungin S, Malovani H, Albeck M, Okun E, Nir U, Sredni B.
    Ann N Y Acad Sci; 2007 Jan 15; 1095():240-50. PubMed ID: 17404037
    [Abstract] [Full Text] [Related]

  • 11. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
    Kalechman Y, Rushkin G, Nerubay J, Albeck M, Sredni B.
    Exp Hematol; 1995 Dec 15; 23(13):1358-66. PubMed ID: 7498364
    [Abstract] [Full Text] [Related]

  • 12. Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis.
    Halpert G, Eitan T, Voronov E, Apte RN, Rath-Wolfson L, Albeck M, Kalechman Y, Sredni B.
    J Biol Chem; 2014 Jun 13; 289(24):17215-27. PubMed ID: 24764299
    [Abstract] [Full Text] [Related]

  • 13. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.
    Sredni B, Kalechman Y, Albeck M, Gross O, Aurbach D, Sharon P, Sehgal SN, Gurwith MJ, Michlin H.
    Immunology; 1990 Aug 13; 70(4):473-7. PubMed ID: 2118479
    [Abstract] [Full Text] [Related]

  • 14. Production of the novel mesangial autocrine growth factors GDNF and IL-10 is regulated by the immunomodulator AS101.
    Kalechman Y, Sredni B, Weinstein T, Freidkin I, Tobar A, Albeck M, Gafter U.
    J Am Soc Nephrol; 2003 Mar 13; 14(3):620-30. PubMed ID: 12595497
    [Abstract] [Full Text] [Related]

  • 15. The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme.
    Brodsky M, Yosef S, Galit R, Albeck M, Longo DL, Albeck A, Sredni B.
    J Interferon Cytokine Res; 2007 Jun 13; 27(6):453-62. PubMed ID: 17572009
    [Abstract] [Full Text] [Related]

  • 16. Up-regulation by ammonium trichloro(dioxoethylene-0,0') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101.
    Kalechman Y, Strassmann G, Albeck M, Sredni B.
    J Immunol; 1998 Oct 01; 161(7):3536-42. PubMed ID: 9759874
    [Abstract] [Full Text] [Related]

  • 17. Immunomodulating tellurium compounds as anti-cancer agents.
    Sredni B.
    Semin Cancer Biol; 2012 Feb 01; 22(1):60-9. PubMed ID: 22202556
    [Abstract] [Full Text] [Related]

  • 18. Increased DNA repair ability after irradiation following treatment with the immunomodulator AS101.
    Kalechman Y, Shani A, Albeck M, Sotnik Barkai I, Sredni B.
    Radiat Res; 1993 Nov 01; 136(2):197-204. PubMed ID: 8248476
    [Abstract] [Full Text] [Related]

  • 19. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma.
    Kalechman Y, Shani A, Dovrat S, Whisnant JK, Mettinger K, Albeck M, Sredni B.
    J Immunol; 1996 Feb 01; 156(3):1101-9. PubMed ID: 8557985
    [Abstract] [Full Text] [Related]

  • 20. The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis.
    Xie L, Chen J, McMickle A, Awar N, Nady S, Sredni B, Drew PD, Yu S.
    J Neuroimmunol; 2014 Aug 15; 273(1-2):31-41. PubMed ID: 24975323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.